Maximum quantity allowed is 999
Please select the quantity
CAS RN: 66898-62-2 | Product Number: T3101
Talniflumate
×
![]()
×
Purity: >98.0%(HPLC)(N)
Synonyms:
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 200MG |
NT$3,440
|
15 | 23 | It can be shipped in about 2 weeks after ordering | |
| 1G |
NT$11,320
|
3 | 2 | It can be shipped in about 2 weeks after ordering |
* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact
our distributor
in Taiwan to order our product.
* The storage conditions are subject to change without notice.
| Product Number | T3101 |
| Purity / Analysis Method | >98.0%(HPLC)(N) |
| Molecular Formula / Molecular Weight | C__2__1H__1__3F__3N__2O__4 = 414.34 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 66898-62-2 |
| Reaxys Registry Number | 503261 |
| PubChem Substance ID | 253662062 |
| Merck Index (14) | 9044 |
| MDL Number | MFCD00866135 |
Specifications
| Appearance | White to Yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 98.0 % |
| Melting point | 166.0 to 170.0 °C |
Properties (reference)
| Melting Point | 168 °C |
| Maximum Absorption Wavelength | 287(CHCl3) nm |
GHS
Related Laws:
| RTECS# | QT2999200 |
Transport Information:
| H.S.code* | 2933.39-000 |
Application
Talniflumate: An Inhibitor of Human Calcium-Activated Chloride Channels
Talniflumate, also known as MSI-1995, is an inhibitor of human calcium-activated chloride channels. It is a prodrug of niflumic acid [T2353]. It was originally developed as an anti-inflammatory agent, but is currently being developed as a mucous regulator for the treatment of cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and asthma. (The product is for research purpose only.)
References
- Pharmacokinetics of talniflumate, a prodrug of niflumic acid, following oral administration to man
- Talniflumate (Genaera) (a review)
- D. Knight, Curr. Opin. Invest. Drugs 2004, 5, 557.
- Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome
- Effect of food on systemic exposure to niflumic acid following postprandial administration of talniflumate
- Simultaneous determination of niflumic acid and its prodrug, talniflumate in human plasma by high performance liquid chromatography
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.